Pathologic Reassessment of Prostate Cancer Surgical Specimens Before Molecular Retrospective Studies

Fromont, Gaëlle; Validire, Pierre; Prapotnich, Dominique; Rozet, François; Vallancien, Guy; Cussenot, Olivier; Cathelineau, Xavier

doi:10.1158/1078-0432.ccr-10-1046

Cited by 8 publications

(5 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Retrospective review of pathology may be necessary in the evaluation of patient outcome when historical cases are involved. 1,13 In this study, Gleason score was an independent predictor of biochemical recurrence along with patient age, PSA, surgical margin, and prostatic volume. Interestingly, Gleason score was the only independent predictor of the development of metastasis.…”

Section: Discussionmentioning

confidence: 63%

Impact on the Clinical Outcome of Prostate Cancer by the 2005 International Society of Urological Pathology Modified Gleason Grading System

Dong¹,

Wang²,

Farris³

et al. 2012

American Journal of Surgical Pathology

View full text Add to dashboard Cite

The 2005 International Society of Urological Pathology (ISUP) Consensus Conference modified the Gleason grading system for prostate cancer. In the modified criteria, ill-defined glands with poorly formed lumina and large cribriform glands with smooth borders, classically described as Gleason pattern 3 adenocarcinoma, were redefined as Gleason pattern 4. To evaluate the clinical outcome of patients upgraded by the ISUP criteria, the histologic slides of 1240 consecutive radical prostatectomy specimens at a single institution were reviewed, and each case of adenocarcinoma was graded on the basis of the original and modified Gleason criteria. A total of 806 patients with prostate cancer of classical Gleason score 3+3=6 or 3+4=7 and modified Gleason score 6 to 8 were analyzed with a median overall follow-up of 12.6 years. In the study population, 34% of patients with classical Gleason score 3+3=6 prostate cancer were upgraded to modified Gleason score 7 or 8 by the ISUP criteria. Compared to patients with modified Gleason score 3+3=6 and patients with classical Gleason score 3+4=7, the upgraded patients were at intermediate risk for biochemical progression (paired log-rank P≤0.003) and metastasis (paired log-rank P≤0.04) after radical prostatectomy. The hazard ratio for upgrading was 1.60 (95% confidence interval, 1.09-2.35, P=0.02) for biochemical recurrence and 5.02 (95% confidence interval, 1.77-14.2, P=0.003) for metastasis. These results validate the prognostic value of the modified Gleason grading system and suggest that the recognition of an intermediate-risk histological pattern may be useful in the prognosis of patients with prostate cancer.

show abstract

Section: Discussionmentioning

confidence: 63%

Impact on the Clinical Outcome of Prostate Cancer by the 2005 International Society of Urological Pathology Modified Gleason Grading System

Dong¹,

Wang²,

Farris³

et al. 2012

American Journal of Surgical Pathology

View full text Add to dashboard Cite

show abstract

“…The constructed database should later be completed with information regarding survival. Previous reports have indicated that there is a certain level of discrepancy in diagnoses of tumours when the original and the reassessment results are compared . Both down‐grading and up‐grading of tumours have been reported.…”

Section: Discussionmentioning

confidence: 99%

“…Previous reports have indicated that there is a certain level of discrepancy in diagnoses of tumours when the original and the reassessment results are compared. [20][21][22][23] Both down-grading and up-grading of tumours have been reported. In line with previous reports, we also noted a certain level of discrepancy (85% agreement rate) when the archival material included in this study was reassessed.…”

Section: Discussionmentioning

confidence: 99%

Subtyping of gliomas of various WHO grades by the application of immunohistochemistry

et al. 2013

View full text Add to dashboard Cite

AimsIn 2010, four subtypes (classical, proneural, mesenchymal, and neural) of glioblastoma multiforme (GBM) were defined by molecular genetic analyses. The objective of this study was to assess whether gliomas, independently of the type and grade, could be subdivided into protein-based subtypes.Methods and resultsA tissue microarray (TMA) approach was applied to incorporate tissue samples of low-grade and high-grade gliomas into five TMAs. High expression levels of epidermal growth factor receptor (EGFR), CD44, c-MER proto-oncogene tyrosine kinase (MERTK), platelet-derived growth factor receptor α, p53, oligodendrocyte transcription factor 2 (OLIG2) and isocitrate dehydrogenase 1 with the R132H mutation were assessed using immunohistochemistry (IHC). Glioma could be subdivided into four subtypes by IHC. The majority of the low-grade gliomas were of the proneural subtype, i.e. high p53 expression (63% of grade II). The classical subtype, with high EGFR and low p53 expression, was most common in GBMs (39%), followed by the proneural (29%) and mesenchymal (with high CD44 and MERTK expression) (29%) subtypes, a frequency that is in line with previously published data based on molecular genetics.ConclusionsAssessment of the expression of the five proteins EGFR, CD44, MERTK, p53 and OLIG2 is sufficient for subtyping gliomas, and can be recommended for implementation in clinical practice for both low-grade and high-grade gliomas.

show abstract

“…Moreover, we choose to select only patients with negative surgical margins, in order to eliminate the biases due to the impact of positive margin size on disease outcome. In addition, all the selected tumors were carefully reassessed after centralized review, since we recently demonstrated the importance to review the pathological characteristics of prostate cancer surgical specimens before molecular studies performed on retrospective cases 30.…”

Section: Discussionmentioning

confidence: 99%

BCAR1 expression improves prediction of biochemical reccurence after radical prostatectomy

et al. 2012

Self Cite

View full text Add to dashboard Cite

show abstract

Pathologic Reassessment of Prostate Cancer Surgical Specimens Before Molecular Retrospective Studies

Cited by 8 publications

References 22 publications

Impact on the Clinical Outcome of Prostate Cancer by the 2005 International Society of Urological Pathology Modified Gleason Grading System

Impact on the Clinical Outcome of Prostate Cancer by the 2005 International Society of Urological Pathology Modified Gleason Grading System

Subtyping of gliomas of various WHO grades by the application of immunohistochemistry

BCAR1 expression improves prediction of biochemical reccurence after radical prostatectomy

Contact Info

Product

Resources

About